This is a Phase I, first time in human, randomised, double-blind, placebo-controlled, and dose escalation study.~The study will comprise of:~A Screening Period of up to 27 days (Day -28 through Day -2);~A Treatment Period during which participants will be resident at the Clinical Unit from Day -1, 1 day before Investigational Medicinal Product (IMP) administration (on Day 1) until at least 24 hours after IMP administration, will be discharged on Day 2 after all safety evaluations have been completed, and~A Follow up Period lasting 360 days (through to Day 361) after the IMP dose.~The study will be conducted at a single study centre in United Kingdom.
In this first-in-humans dose escalation study, AZD7442 (AZD8895 + AZD1061) will be evaluated for safety, tolerability, pharmacokinetics, and generation of anti-drug antibodies (ADAs). The study is intended to enable future studies of AZD7442's efficacy in preventing and treating COVID-19.